Genetically modified major histocompatibility complex mice
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsLynn Macdonald, Andrew J. Murphy, Naxin Tu, Cagan Gurer, Vera Voronina, Sean Stevens
Life of this patent
Estimating the term…
Abstract
The invention provides genetically modified non-human animals that express a humanized MHC II protein (humanized MHC II α and β polypeptides), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
Claims26
A non-human animal comprising at an endogenous Major Histocompatibility Complex II (MHC II) α gene locus a nucleotide sequence encoding a chimeric human/non-human MHC II α polypeptide,
- wherein a human portion of the chimeric human/non-human MHC II α polypeptide comprises a human MHC II α extracellular domain, and
- wherein the animal expresses a functional MHC II complex on a surface of a cell of the animal.
A non-human animal comprising at an endogenous MHC II β gene locus a nucleotide sequence encoding a chimeric human/non-human MHC II β polypeptide,
- wherein a human portion of the chimeric human/non-human MHC II β polypeptide comprises a human MHC II β extracellular domain, and
- wherein the animal expresses a functional MHC II complex on a surface of a cell of the animal.
19-34. (canceled)
A method of modifying an MHC II locus of a mouse to express a chimeric human/mouse MHC II complex comprising replacing at the endogenous mouse MHC II locus a nucleotide sequence encoding a mouse MHC II complex with a nucleotide sequence encoding a chimeric human/mouse MHC II complex.
Dependencies are inferred from the claim text.